Efficacy and safety of home enteral nutritional support in postoperative gastric cancer patients: A systematic review and meta-analysis.
[BACKGROUND AND AIMS] Poor nutritional status markedly elevates postoperative risk in patients with gastric cancer.
- p-value p < 0.05
- 95% CI -1.63 to -0.48
- 연구 설계 meta-analysis
APA
Zhu C, Wang Y, et al. (2026). Efficacy and safety of home enteral nutritional support in postoperative gastric cancer patients: A systematic review and meta-analysis.. Clinical nutrition (Edinburgh, Scotland), 60, 106626. https://doi.org/10.1016/j.clnu.2026.106626
MLA
Zhu C, et al.. "Efficacy and safety of home enteral nutritional support in postoperative gastric cancer patients: A systematic review and meta-analysis.." Clinical nutrition (Edinburgh, Scotland), vol. 60, 2026, pp. 106626.
PMID
41895151
Abstract
[BACKGROUND AND AIMS] Poor nutritional status markedly elevates postoperative risk in patients with gastric cancer. Evidence regarding the benefits and safety of home enteral nutrition (HEN) after discharge remains inconclusive. This meta-analysis assessed the effectiveness and safety of HEN following gastrectomy based on available studies.
[METHODS] This systematic review followed the PRISMA guidance. We searched the Cochrane Library, Web of Science, Embase, PubMed, CNKI, Wanfang, SinoMed, VIP, and ProQuest from inception to December 11, 2024, and screened trial registration and preprint platforms. Randomized controlled trials (RCTs) and quasi-experimental studies published in English or Chinese were included. Risk of bias was assessed using the Cochrane ROB-2 and ROBINS-I tools, and meta-analyses were conducted using R (version 4.4).
[RESULTS] Sixteen RCTs and four quasi-experimental studies involving 2969 patients were included. HEN demonstrated a positive effect on nutritional intake and reduced weight loss (MD = -1.06; 95% CI: -1.63 to -0.48; 95% PI: -2.12 to 0.01; p < 0.05; τ = 0.15; I = 45.6%). HEN improved total protein (SMD = 0.35; 95% CI: 0.04 to 0.65; 95% PI: -0.52 to 1.21; p < 0.05; τ = 0.13; I = 77.2%), albumin (SMD = 0.40; 95% CI: 0.03 to 0.76; 95% PI: -0.79 to 1.58; p < 0.05; τ = 0.27; I = 88.2%), prealbumin (SMD = 0.60; 95% CI: 0.20 to 1.01; 95% PI: -0.32 to 1.53; p < 0.05; τ = 0.11; I = 63.3%), and subjective nutritional status (MD = -1.66; 95% CI: -2.53 to -0.79; 95% PI: -3.85 to 0.53; p < 0.05; τ = 0.61; I = 87.0%). HEN did not increase readmission or complication rates and improved quality of life, particularly physical function (MD = 6.36; 95% CI: 2.55 to 10.16; 95% PI: -0.97 to 13.68; p < 0.05; τ = 5.93; I = 61.8%) and appetite loss (MD = -6.87; 95% CI: -11.03 to -2.71; 95% PI: -12.66 to -1.08; p < 0.05; τ = 1.06; I = 9.0%).
[CONCLUSIONS] HEN appears promising in reducing postoperative weight loss, improving nutritional status, supporting chemotherapy tolerance, and enhancing quality of life; however, its overall efficacy remains uncertain.
[METHODS] This systematic review followed the PRISMA guidance. We searched the Cochrane Library, Web of Science, Embase, PubMed, CNKI, Wanfang, SinoMed, VIP, and ProQuest from inception to December 11, 2024, and screened trial registration and preprint platforms. Randomized controlled trials (RCTs) and quasi-experimental studies published in English or Chinese were included. Risk of bias was assessed using the Cochrane ROB-2 and ROBINS-I tools, and meta-analyses were conducted using R (version 4.4).
[RESULTS] Sixteen RCTs and four quasi-experimental studies involving 2969 patients were included. HEN demonstrated a positive effect on nutritional intake and reduced weight loss (MD = -1.06; 95% CI: -1.63 to -0.48; 95% PI: -2.12 to 0.01; p < 0.05; τ = 0.15; I = 45.6%). HEN improved total protein (SMD = 0.35; 95% CI: 0.04 to 0.65; 95% PI: -0.52 to 1.21; p < 0.05; τ = 0.13; I = 77.2%), albumin (SMD = 0.40; 95% CI: 0.03 to 0.76; 95% PI: -0.79 to 1.58; p < 0.05; τ = 0.27; I = 88.2%), prealbumin (SMD = 0.60; 95% CI: 0.20 to 1.01; 95% PI: -0.32 to 1.53; p < 0.05; τ = 0.11; I = 63.3%), and subjective nutritional status (MD = -1.66; 95% CI: -2.53 to -0.79; 95% PI: -3.85 to 0.53; p < 0.05; τ = 0.61; I = 87.0%). HEN did not increase readmission or complication rates and improved quality of life, particularly physical function (MD = 6.36; 95% CI: 2.55 to 10.16; 95% PI: -0.97 to 13.68; p < 0.05; τ = 5.93; I = 61.8%) and appetite loss (MD = -6.87; 95% CI: -11.03 to -2.71; 95% PI: -12.66 to -1.08; p < 0.05; τ = 1.06; I = 9.0%).
[CONCLUSIONS] HEN appears promising in reducing postoperative weight loss, improving nutritional status, supporting chemotherapy tolerance, and enhancing quality of life; however, its overall efficacy remains uncertain.
MeSH Terms
Humans; Enteral Nutrition; Stomach Neoplasms; Gastrectomy; Nutritional Status; Postoperative Care; Home Care Services; Randomized Controlled Trials as Topic; Postoperative Complications; Treatment Outcome; Weight Loss; Female
같은 제1저자의 인용 많은 논문 (5)
- LRP8 Promotes colorectal cancer progression by suppressing ferroptosis through the SLC3A2/GPX4 signalling axis.
- Synchronous breast carcinoma and diffuse large B-cell lymphoma: a case report and literature review on diagnostic challenges and management implications.
- A DNA Methylation-Dependent NOP56/MYC Positive Feedback Loop Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Through Regulating Ribosome Biogenesis.
- Lifestyle factors and all-cause mortality in long-term cancer survivors: a population-based prospective cohort study.
- Water flow-driven electrocatalytic system coupling redox processes for the deep mineralization of halogenated organic compounds.